Sangamo receives U.S. FDA Fast Track Designation to ST-503

Sangamo (SGMO) Therapeutics announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track Designation to ST-503, an investigational epigenetic regulator for the treatment of intractable pain due to small fiber neuropathy, SFN, a type of chronic neuropathic pain. “We are very pleased to receive FDA Fast Track Designation for ST-503. SFN is a debilitating chronic pain disorder, with limited effective treatment options currently available,” said Nathalie Dubois-Stringfellow, Ph.D., Sangamo’s Chief Development Officer. “This designation underscores the high unmet patient need in SFN and the urgency to develop safe and effective nonopioid treatment alternatives. We are preparing to dose the first patient in our Phase 1/2 study and look forward to sharing data once available.”